The case for & against
Bull & Bear analysis
Alkermes PLC (NASDAQ: ALKS) is a biopharmaceutical company specializing in the development of innovative therapies for chronic conditions focused primarily in neuroscience, specifically disorders linked to sleep and addiction. Recently, Alkermes has made strategic moves into the sleep medicine market through its acquisition of Avidel Pharmaceuticals, acquiring the FDA-approved product Lumerize for narcolepsy treatment. The company operates a vertically integrated model encompassing drug development, manufacturing, and commercialization, positioning itself uniquely to capitalize on upcoming market opportunities.
Bull says
- ↑Q2 revenues $496 M, up 34% YoY on proprietary product strength
- ↑2026 revenue guided at $1.73–1.84 B, reflecting strong outlook
- ↑Avidel acquisition adds $265–275 M Lumerize revenue in 2025
- ↑$690 M cash on hand supports R&D and strategic initiatives
- ↑Phase III Elixirexin trials poised to enter narcolepsy market
- ↑Strong momentum and liquidity factors signal positive market interest
Bear says
- ↓Projected GAAP net loss of $115–135 M pressures earnings
- ↓Q2 R&D expenses climbed 46% to $112.9 M, heightening margin risk
- ↓Weak profitability indicators suggest revenue‐to‐net‐income conversion issues
- ↓Competition from Eli Lilly in sleep medicine may erode pricing
- ↓FDA approval timelines for Elixirexin carry regulatory uncertainty
- ↓Low earnings yield and book‐to‐price ratios reflect valuation concerns
Investment themes with ALKS
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- Vibrance 1, elixirexin showed dose-dependent, statistically significant, and clinically meaningful increases in mean sleep latency at all doses tested at week 6.
- across all doses tested, elixirexin demonstrated statistically significant and clinically meaningful improvement at week six, with each dose group achieving normative levels.
- elixirexin